Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Completed
The primary purpose of this clinical research study is to learn if patients treated with the combination of Taxane/Carboplatin plus Cetuximab (C/T/C) have a longer progression-free survival than patients treated with Taxane/Carboplatin (T/C) alone. The safety of this treatment will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/24/2015
Locations: Local Institution, Birmingham, Alabama +1 locations
Conditions: Non-Small-Cell Lung Carcinoma
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if carboplatin is more effective with or without liposomal doxorubicin in treating recurrent ovarian epithelial or primary peritoneal cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of carboplatin with or without liposomal doxorubicin in treating patients who have recurrent o... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
10/23/2015
Locations: MBCCOP - Gulf Coast, Mobile, Alabama
Conditions: Ovarian Cancer, Peritoneal Cavity Cancer
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Completed
This randomized phase III trial studies carboplatin, paclitaxel, and sorafenib tosylate to see how well they work compared to carboplatin and paclitaxel in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib tosylate may stop the growth of tumor cells by blocking some... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/28/2015
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Conditions: Mucosal Melanoma, Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Completed
This randomized phase II trial is comparing three different combination chemotherapy regimens to see how well they work in treating patients with relapsed or refractory acute myeloid leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/02/2015
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
Completed
Multicenter randomized phase II trial to examine the safety and efficacy of carboplatin, docetaxel, bevacizumab followed by maintenance bevacizumab and erlotinib in patients with completely resected stage IB, II, and select III NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2015
Locations: Northeast Alabama Medical Center, Anniston, Alabama
Conditions: Non-Small Cell Lung Cancer
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
Terminated
This is a randomized trial to estimate the activity of R-ICE plus SGN-40 vs. R-ICE plus placebo in patients with DLBCL. The study will assess safety and tolerability and will measure any additional clinical benefit observed in patients receiving SGN-40.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/06/2015
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)
Completed
The primary objective of Part I of the study is to determine tumor response rate of sequential topoisomerase targeting with irinotecan/oxaliplatin followed by etoposide /carboplatin in chemotherapy-naïve patients with extensive small cell lung cancer. The primary objective of Part II of the study is to determine the objective tumor response rate of irinotecan/oxaliplatin in patients with either refractory disease or who have relapsed to first line chemotherapy or chemoradiotherapy.
Gender:
ALL
Ages:
Between 19 years and 80 years
Trial Updated:
11/26/2014
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Non-Small Cell Lung Cancer
Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
Completed
RATIONALE: Amifostine may be an effective treatment for the toxic side effects caused by radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without amifostine for non-small cell lung cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of amifostine in treating patients who have stage II or stage III non-small cell lung cancer that cannot be surgically removed and who are undergoing chemotherapy and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2014
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +5 locations
Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
Completed
The purpose of this Phase 3 study is to evaluate overall survival and progression free survival following intravenous administration of REOLYSIN (Reovirus Serotype 3 Dearing) in combination with paclitaxel and carboplatin versus chemotherapy treatment alone, in patients with metastatic or recurrent Squamous Cell Carcinoma of the Head and Neck.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2014
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Carcinoma, Squamous Cell of the Head and Neck
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Terminated
A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2014
Locations: Not set, Birmingham, Alabama +1 locations
Conditions: Carcinoma, Non-Small Cell Lung
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Completed
The objectives of this study are to compare the anti-tumor activity as measured by Progression Free Survival (PFS) and tolerability of Sorafenib in combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in combination with placebo in subjects with unresectable Stage III or Stage IV melanoma who progressed after receiving only one prior therapy containing Dacarbazine (DTIC) or Temozolomide (TMZ).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2014
Locations: Not set, Birmingham, Alabama
Conditions: Melanoma
Combination Chemotherapy in Treating Children With Neuroblastoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Combination chemotherapy plus surgery may be an effective treatment for neuroblastoma. PURPOSE: This phase III trial is studying how well combination chemotherapy followed by surgery works in treating young patients with neuroblastoma.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
07/31/2014
Locations: Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama +1 locations
Conditions: Neuroblastoma